Topical Psoralen And Ultraviolet A Radiation Treatment For Alopecia Areata

Abstract

With an enigmatic etiology, there is neither a permanent cure for alopecia areata nor a universally proven therapy inducing remission. This study aims to showing the efficacy of topical PUVA-SOL in the treatment of alopecia areata, and immunomodulatory effect of topical PUVA-SOL therapy. One hundred and fifty patients with AA attending Department of Dermatology at Tikrit Teaching Hospital were enrolled in this study in the period December 2008 through to December 2009; there were 1oo cases (66.66%) and 50 controls (33.33%). All patients were examined clinically, then interviewed and detailed AA questionnaires were completed for each of them. All patients included in this study suffered from AA, which failed to response to conventional therapy. The most common site for AA found in the scalp. The AA more common in male than female, and more common in the young age than old age. The response of lesions to treatment were 68% in the cases, and 13% in the control while not response 32% in the cases, and 87% in the control. The time of response to treatment more visible after 20 weeks of treatment among cases and control.